STIM — Neuronetics, Inc.

Nasdaq · Health Care · Health Care Equipment & Supplies · CIK 1227636 ·
Last close
$1.21
Market Cap
$84.20M
52W High
$2.47
52W Low
$1.12
ADV30
2,327,380
Next earnings
2026-08-04
Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company provides NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. has a strategic collaboration with ANT Neuro to expand the capabilities of the NeuroStar advanced therapy system with advanced image-guided navigation technology. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 34,454,000 16,154,000 -8,995,000 -10,790,000 125,440,000 13,214,000 108,380,000
Dec 2025 41,777,000 21,704,000 -5,043,000 -7,158,000 141,551,000 28,134,000 115,311,000
Sep 2025 37,297,000 17,108,000 -7,321,000 -9,045,000 145,465,000 27,971,000 114,105,000
Jun 2025 38,108,000 17,758,000 -8,058,000 -10,120,000 134,650,000 10,969,000 103,143,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-20,374,000
Investing CF
$-801,000
Financing CF
$35,850,000
CapEx
$-801,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-0.59
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-458,787,000
Inventory
$4,327,000
Receivables
$16,893,000
ST Investments
$225,000
EBIT TTM
$-31,520,000
Pretax Income TTM
$-39,120,000
Interest Exp TTM
$7,600,000
Analysts
3

Yahoo Snapshot (yfinance, live)

Total Revenue
$151,636,000
EBITDA
$-25,778,000
Free Cash Flow
$-4,582,000
Enterprise Value
$159,474,400
Total Cash
$13,214,000
Total Debt
$85,388,000
Shares Out
69,587,840
Trailing EPS
$-0.54
Book Value
$0.19
ROE
-131.6%
ROA
-13.6%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 149,157,000 -31,436,000 -38,998,000 141,551,000 115,311,000 -20,374,000
Dec 2024 74,890,000 -34,563,000 -43,708,000 140,903,000 109,104,000 -30,997,000
Dec 2023 71,348,000 -30,554,000 -30,189,000 115,831,000 81,641,000 -32,038,000
Dec 2022 65,206,000 -35,111,000 -37,159,000 116,884,000 59,824,000 -30,739,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-0.34

Max Pain — expiry 2026-08-21 (volume-derived — Yahoo OI feed degraded)

max pain strike: $1.00 · spot: $1.21 · call volume: 213 · put volume: 12
Expected Move to 2026-08-21: ±$0.99 (81.82%) — implied range $0.22$2.20 · ATM straddle on $1.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
SKIN SkinHealth Systems Inc. $84.23M $0.65
EBRCZ EBR Systems, Inc. $84.30M $0.19
NRXS Neuraxis, INC $83.10M $6.71
PYPD PolyPid Ltd. $87.43M $4.56
SNWV SANUWAVE Health, Inc. $78.16M $9.09

News headlines (Yahoo Finance, 1h cache)

Neuronetics Appoints Robert Greene as Senior Vice President Sales
2026-06-02 20:30 · Yahoo
Neuronetics Highlights Continued Advancements in TMS Research at CTMSS 2026
2026-06-02 12:32 · Yahoo
Lungpacer Medical Appoints Steven Pfanstiel as Chief Financial Officer
2026-06-01 11:00 · Yahoo
Neuronetics and ANT Neuro Announce Strategic Collaboration to Integrate Neuronavigation with NeuroStar TMS Treatment
2026-05-14 12:32 · Yahoo
Neuronetics Q1 Earnings Call Highlights
2026-05-05 21:07 · Yahoo
Neuronetics, Inc. Q1 2026 Earnings Call Summary
2026-05-05 20:55 · Yahoo
Neuronetics (STIM) Q1 2026 Earnings Transcript
2026-05-05 20:20 · Yahoo
Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates
2026-05-05 13:15 · Yahoo
Neuronetics Reports First Quarter 2026 Financial and Operating Results
2026-05-05 11:50 · Yahoo
How The Neuronetics (STIM) Investment Story Is Evolving With A Reset Price Target
2026-05-02 14:14 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.